As advised via PHARMAC tender of 30 April 2018 there is to be a change in the listing and future sole supply.

New listing from 1 November 2018

Trexate Tab 2.5 mg 90                                                                                     Pharmacode 2537060             Schedule price $8.05

Trexate Tab 10 mg 90                                                                                      Pharmacode 2537079             Schedule price $31.75

Incumbent brand

Trexate Tab 2.5 mg 30                                                                                    Pharmacode 2404494              Schedule price $3.18

Trexate Tab 10 mg 50                                                                                     Pharmacode 2404508              Schedule price $21.00

Reference pricing will apply to the incumbent from 1 January 2019.

HML (Hospital Supply Status) commences 1 January 2019 and CSS (Community Supply Status) commences 1 April 2019.

As of the date of this notification ProPharma / PWR cannot accept Trexate 2.5 mg 30 or 10 mg 50 for credit under any circumstances.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

Benefit of staying with incumbent – With a variable or reducing margin every cent counts.

2.5 mg:-  $3.18 x 3% = $0.0954 plus $0.7590 ($0.2530 x 3 to be equivalent number of tablets) per pack fee = $0.8544  compared to $8.05 x 3% = $0.2415 plus $0.2530  per pack fee = $0.4945. Overall $0.3599

10 mg:-  $37.80 x 3% = $1.1340 plus $0.4284 (equivalent number of tablets/packs) per pack fee = $1.5894 compared to $31.75 x 3% = $0.9525 plus $0.2530  per pack fee = $1.2055. Overall $0.3839

You MUST manage your stock so that you have ZERO stock at time of reference pricing being 1 January 2019 or have been advised of supplier price change/support earlier. No matter what you must manage your stock accordingly.

Once again we need your support to ensure stock in the supply chain moves through to effectively ensure no losses are incurred.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author

Close